|Application ||WB, IHC-P, E|
|Other Accession||AAS82846, 46241139|
|Calculated MW||18120 Da|
|Application Notes||IL-31 antibody can be used for the detection of IL-31 by Western blot at 2.5 - 10 µg/mL. Antibody can also be used for immunohistochemistry starting at 10 µg/mL.|
|Other Names||IL-31 Antibody: 1700013B14Rik, Interleukin-31, IL-31, interleukin 31|
|Reconstitution & Storage||IL-31 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||IL-31 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Activates STAT3 and possibly STAT1 and STAT5 through the IL31 heterodimeric receptor composed of IL31RA and OSMR (PubMed:15184896). May function in skin immunity (PubMed:15184896). Enhances myeloid progenitor cell survival in vitro (PubMed:17379091). Induces RETNLA and serum amyloid A protein expression in macrophages (PubMed:25847241).|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
IL-31 Antibody: Interleukin-31 (IL-31) is a recently discovered T-cell cytokine closely related to IL-6 type cytokines and is preferentially produced by T helper type 2 cells. IL-31 activity is mediated through the ligand-induced oligomerization of a dimeric receptor complex containing IL-31 receptor A and oncostatin M receptor. In response to IL-31 binding, these proteins activate the JAK/STAT and the AKT signaling pathways. RNA levels of IL-31 receptor A and oncostatin M receptor are induced in activated monocytes but are expressed constitutively in epithelial cells. IL-31, when overexpressed in transgenic mice, results in the development of pruritis, alopecia, and skin lesions and in humans may result in atopic dermatitis, suggesting that IL-31 may represent a novel target for antipruritic drug development.
Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat. Immunol. 2004; 5:752-60.
Dreuw A, Radtke S, Pflanz S, et al. Characterization of the signaling capacities of the novel gp130-like cytokine receptor. J. Biol. Chem. 2004; 279:36112-20.
Diveu C, Lak-Hal AH, Froger J, et al. Predominant expression of the long isoform of GP130-like (GPL) receptor is required for interleukin-31 signaling. Eur. Cytokine Netw. 2004; 15:291-302.
Bilsborough J, Leung DY, Maurer M, et al. IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J. Allergy Clin. Immunol. 2006; 117:418-25.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.